Vaxcyte, Inc. PCVX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $958.95M+80.9% | $794.31M+66.6% | $685.86M+53.4% | $592.86M+38.6% | $530.19M+43.7% | ||
| $129.78M+22.8% | $129.37M+39.3% | $125.7M+53.5% | $116.24M+56.1% | $105.68M+56.6% | ||
| $1.09B+71.2% | $923.68M+62.2% | $811.56M+34.4% | $709.11M+22.9% | $635.87M+24.4% | ||
| -$1.09B-71.2% | -$923.68M-62.2% | -$811.56M-34.4% | -$709.11M-22.9% | -$635.87M-24.4% | ||
| $142.2M+12.6% | $157.05M+48.7% | $154.36M+60.1% | $161.61M+102% | $126.24M+69.5% | ||
| -$946.53M-85.7% | -$766.63M-65.2% | -$657.2M-29.5% | -$547.5M-10.1% | -$509.63M-16.7% | ||
| -$6.88-72.4% | -$5.62-47.9% | -$4.84-5.2% | -$4.11+12.2% | -$3.99+6.8% | ||
| -$1.07B-71.1% | -$907.28M-61.3% | -$799.8M-33.5% | -$698.62M-21.9% | -$626.91M-23.4% | ||
| -$1.09B-71.2% | -$923.68M-62.2% | -$811.56M-34.4% | -$709.11M-22.9% | -$635.87M-24.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vaxcyte, Inc. profitable?
- Vaxcyte, Inc. is not currently profitable: it reported a net loss of $946.5M over the trailing twelve months.
- What is Vaxcyte, Inc.'s earnings per share?
- Vaxcyte, Inc.'s diluted EPS over the trailing twelve months is $-6.88.
- Where does Vaxcyte, Inc.'s income statement data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.